Logo.PNG
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
January 08, 2024 07:00 ET | HilleVax, Inc.
BOSTON and CHENGDU, China, Jan. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, and...
Logo.PNG
HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 18:28 ET | HilleVax, Inc.
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
22157.jpg
Quadrivalent Virus-Like Particle (VLP) Vaccine Emerging Drug Insights and Market Forecasts, 2019-2022 and 2023-2032
December 14, 2023 10:03 ET | Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Quadrivalent VLP vaccine Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report...
MnM_logo_TM_JPG.JPG
ELISpot and FluoroSpot Assay Market is Expected to Reach $421 million | MarketsandMarkets.
December 04, 2023 07:30 ET | MarketsandMarkets Research Pvt. Ltd.
Chicago, Dec. 04, 2023 (GLOBE NEWSWIRE) -- ELISpot and FluoroSpot Assay market in terms of revenue was estimated to be worth $292 million in 2023 and is poised to reach $421 million by 2028, growing...
22157.jpg
mRNA Platform Market Research Report 2023 - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F
December 01, 2023 06:18 ET | Research and Markets
Dublin, Dec. 01, 2023 (GLOBE NEWSWIRE) -- The "mRNA Platform Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F" report has been added to ResearchAndMarkets.com's...
22157.jpg
North America Digital Vaccine Markets, Competition, Forecast & Opportunities Report 2023-2028 Featuring Friendslearn, Klein Buendel, Evidation Health, Atos, and oVRcome
November 27, 2023 07:18 ET | Research and Markets
Dublin, Nov. 27, 2023 (GLOBE NEWSWIRE) -- The "North America Digital Vaccine Market, Competition, Forecast & Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's...
22157.jpg
Inequitable Access Remains a Challenge in the HBV Vaccine Market Despite Increasing Healthcare Expenditure
November 10, 2023 08:38 ET | Research and Markets
Dublin, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The "Global Hepatitis B Virus (HBV) Vaccine Market (by End User, Composition, & Region): Insights and Forecast with Potential Impact of COVID-19...
Logo.PNG
HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 09, 2023 16:05 ET | HilleVax, Inc.
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
Global Therapeutic Vaccines Market
Global Therapeutic Vaccines Market Analysis 2023-2028: Regulatory Complexities Slow Entry Into the ~$12 Billion-Projected Industry
November 06, 2023 07:48 ET | Research and Markets
Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Therapeutic Vaccines Market (2023-2028) by Product, Disease Indication, Technology, End User, and Geography, Competitive Analysis, Impact of...
Logo.PNG
HilleVax to Present at Upcoming Investor Conferences
November 01, 2023 16:48 ET | HilleVax, Inc.
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...